Respana Therapeutics Inc.

Market/Category

  • Influenza Pneumonia – Therapeutic

Principal Investigator(s) and Department

Clinical Problem

  • Lower respiratory infections remain the deadliest communicable disease, causing 3.2 million deaths worldwide in 2015.
  • Survival of a lower respiratory infection can leave a patient with lifetime chronic pulmonary conditions.

Therapeutic Solution

  • Enhances eradication of the influenza virus, post-influenza pneumonia infections.
  • Decreases harmful inflammation that may lead to hypoxia.
  • Promotes recovery of respiratory function.
  • Reduces the risk of developing secondary bacterial infections in the respiratory system.